Embargoed) CHAPEL HILL — Anemia, a condition arising when the blood contains too few red cells and hence not enough of the oxygen-carrying pigment known
Australian research has led to clinical trials of a drug that could provide a painless and non-destructive way to treat blindness in diabetics. The University
NEW YORK, NY — June 4, 2002 — Antigenics Inc. today announced positive findings from a quality of life study involving the company’s personalized cancer
Sirolimus administered as primary therapy in combination with azathioprine or mycophenolate mofetil, appears to have a favorable safety profile compared to cyclosporin with regards to
An association was noted between laparoscopic donor nephrectomy and increased antidiuretic hormone release, apparently related to increased intra-abdominal pressure, according to Dutch researchers. This relationship
NEW YORK, NY — May 29, 2002 — Antigenics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the company’s personalized
Outcome is poor in patients who have had a renal transplant and who then develop colorectal cancer. Australian researchers suggest immunosuppression and late diagnosis are
NEW YORK (Reuters Health) May 27 – Immunoabsorption therapy immediate prior to kidney transplantation can improve graft survival in patients with anti-human leukocyte antigen (HLA)
NEW YORK (Reuters Health) May 16 – Elevated serum levels of C-reactive protein (CRP) before renal transplant appear to be associated with subsequent chronic allograft
NEW YORK (Reuters Health) May 17 – A renal tubule cell assist device containing human cells has been successfully used to replace kidney function in
NEW YORK (Reuters Health) May 21 – Five years after kidney transplantation, a significant number of patients have sexual problems, headaches, and other ailments that
NEW YORK (Reuters Health) May 22 – Increased angiotensin-converting enzyme (ACE) activity is associated with an increased risk of macroangiopathy and death in patients with
NEW YORK, May 17, 2002 /PRNewswire-FirstCall via COMTEX/ Results of phase III clinical trials with the investigational drug eplerenone, the first selective aldosterone blocker, were
NEW YORK, May 17, 2002 /PRNewswire-FirstCall via COMTEX/ Results of phase III clinical trials with the investigational drug eplerenone, the first selective aldosterone blocker, were
NEW YORK, May 17, 2002 /PRNewswire-FirstCall via COMTEX/ Results of phase III clinical trials with the investigational drug eplerenone, the first selective aldosterone blocker, were
NEW YORK, May 17, 2002 /PRNewswire-FirstCall via COMTEX/ Results of phase III clinical trials with the investigational drug eplerenone, the first selective aldosterone blocker, were
By Jill Stein Special to DG News NEW YORK, NY — May 16, 2002 — Sleep apnea appears to be associated with a higher prevalence
Journal of the American Society of Nephrology, 05/15/2002, By Robert Short Hepatitis C virus accounts for the increased rate of diabetes mellitus observed with tacrolimus-treated
Journal of Renal Nutrition 05/09/2002 By Mark Moran Middle-aged and older maintenance dialysis patients may be at greater risk for developing protein-energy malnutrition than are
ATC: New Investigational Study Reports Two-Dose Zenapax Reduced Incidence Of Acute Organ Rejection in Kidney Transplant Recipients At High Risk for Delayed Organ Function WASHINGTON,